canagliflozin - Robuta Search

https://consultqd.clevelandclinic.org/after-metabolic-surgery-canagliflozin-reduces-bmi-and-blood-glucose-levels-in-patients-with-type-2-diabetes After Metabolic Surgery, Canagliflozin Reduces BMI and Blood Glucose Levels in Patients with Type 2... Patients can expect to lose additional weight on canagliflozin after weight loss plateau following metabolic surgery, according to a recently published... https://adisinsight.springer.com/trials/700358522?error=cookies_not_supported&code=a76ec779-d2be-4e02-a105-9fe8561b0324 A retrospective, cohort study of incidence and predictors to SGLT2i (canagliflozin, empagliflozin)... To describe the incidence and predictors of primary nonadherence to SGLT2i (canagliflozin, empagliflozin) or GLP-1 agonists (dulaglutide, liraglutide, a retrospective cohort study https://www.jnj.com/media-center/press-releases/first-results-from-phase-3-canvas-trial-show-canagliflozin-as-add-on-therapy-to-insulin-lowered-blood-sugar-levels-in-patients-with-type-2-diabetes-at-an-elevated-risk-for-cardiovascular-disease First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered... Jul 18, 2025 - Canagliflozin also shown effective and generally well-tolerated in patients with type 2 diabetes aged 55 to 80 in separate Phase 3 study https://pubmed.ncbi.nlm.nih.gov/35707855/ Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice The aging brain is characterized by progressive increases in neuroinflammation and central insulin resistance, which contribute to neurodegenerative diseases... https://adisinsight.springer.com/drugsafety/803452754?error=cookies_not_supported&code=cede940f-0279-4342-9745-ad2c77642993 Canagliflozin/cefepime - AdisInsight A 73-year-old man and a 75-year-old man were described, of whom the 73-year-old man developed neurotoxicity in the form of decreased consciousness level and canagliflozin cefepime adisinsight https://adisinsight.springer.com/drugsafety/803925076?error=cookies_not_supported&code=00fe3787-f29c-4d35-947b-694726e6680c Acarbose/Canagliflozin - AdisInsight Eleven patients with a history of Roux-en-Y gastric bypass and documented post-bariatric hypoglycaemia received acarbose or canagliflozin and experienced lack acarbose canagliflozin adisinsight https://www.jnj.com/media-center/press-releases/vokanamettm-canagliflozin-and-metformin-fixed-dose-combination-receives-positive-chmp-opinion-recommending-approval-in-the-european-union-for-the-treatment-of-adults-with-type-2-diabetes-1 VOKANAMETTM (canagliflozin and metformin fixed dose combination) receives positive CHMP opinion... canagliflozin metformin fixed https://pmc.ncbi.nlm.nih.gov/articles/PMC5488174/ Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus -... Cardiovascular disease is the most common cause of morbidity and mortality among people with type 2 diabetes mellitus (T2DM). The main contributors to... https://www.ncbi.nlm.nih.gov/Structure/pdb/8HDH 8HDH: Structure of human SGLT2-MAP17 complex with Canagliflozin PDZK1-interacting protein 1Sodium/glucose cotransporter... structure human complex canagliflozin https://www.jnj.com/media-center/press-releases/new-phase-two-proof-of-concept-study-shows-canagliflozin-combination-therapy-may-support-chronic-weight-management New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic... Mar 3, 2025 - Combination of Canagliflozin and Phentermine Demonstrates Improvements in Weight Management in Overweight or Obese Patients without T2DM https://adisinsight.springer.com/drugsafety/803928910?error=cookies_not_supported&code=ae09f39a-df64-4660-b395-99d54f2694af Canagliflozin - AdisInsight A 55-year-old man with a nine-year history of presumed type 2 diabetes mellitus receiving the sodium glucose cotransporter-2 inhibitor canagliflozin experienced canagliflozin adisinsight https://adisinsight.springer.com/drugsafety/803546966?error=cookies_not_supported&code=f8d1a72a-6ff4-41d1-b693-f28005336c96 Canagliflozin/empagliflozin - AdisInsight In a study of the analysis of cases reported in the European pharmacovigilance database (EudraVigilance) from 11 November 2012 to 19 May 2020, a patient [age canagliflozin empagliflozin adisinsight https://adisinsight.springer.com/drugsafety/803527376?error=cookies_not_supported&code=439afac3-4759-49d1-9034-2bb2bf5ddb34 Canagliflozin - AdisInsight A 65-year-old woman developed euglycaemic diabetic ketoacidosis during treatment with canagliflozin for type-2 diabetes mellitus.The woman, who had history of canagliflozin adisinsight https://adisinsight.springer.com/trials/700391348?error=cookies_not_supported&code=b8494062-13cb-47a3-958c-b0bd2249fce4 CANIDIAP; CANagliflozin In DIAlysis Patients - 20725 - AdisInsight The main objective of this exploratory study is to investigate specific tissue distribution of SGLT2 inhibitors in patients on dialysis with-and without canagliflozin dialysis patients adisinsight https://adisinsight.springer.com/drugsafety/803929028?error=cookies_not_supported&code=ab02eb8d-d9ce-4569-b3ee-11e5160d27dc Canagliflozin - AdisInsight A 73-year-old man with type 2 diabetes and end-stage renal disease status post renal transplant, receiving canagliflozin 300 mg [route not stated; duration not canagliflozin adisinsight https://yoda.yale.edu/generic-name/canagliflozin/ Canagliflozin Archives - The YODA Project canagliflozin archives yoda project